Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616941 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00616941 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 28 participants.
The verdict
NCT00616941, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.
Interventions
- BIOLOGICAL NY-ESO-1 OLP4
- BIOLOGICAL NY-ESO-1 OLP4 + Montanide
- BIOLOGICAL NY-ESO-1 OLP4 + Montanide + Poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616941
The ClinicalTrials.gov registry entry for NCT00616941 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which NY-ESO-1 OLP4 is the first listed.
NCT00616941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616941 about?
NCT00616941 is a clinical study titled "Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subj...
What is the current status of trial NCT00616941?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2008-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00616941?
The interventions under investigation include: NY-ESO-1 OLP4 (BIOLOGICAL), NY-ESO-1 OLP4 + Montanide (BIOLOGICAL), NY-ESO-1 OLP4 + Montanide + Poly-ICLC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00616941?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.